Steven Cohen's CTKB Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 422,361 shares of Cytek Biosciences, Inc. (CTKB) worth $1.87 M, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CTKB, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 905,079 shares. Largest reduction occurred in Q3 2022, reducing 862,592 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Cytek Biosciences (CTKB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytek Biosciences (CTKB) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +422,361 | New Buy | 422,361 | $4.43 |
| Q1 2026 | -114,256 | Sold Out | 0 | $0.00 |
| Q4 2025 | -73,362 | Reduce 39.10% | 114,256 | $5.05 |
| Q3 2025 | +187,618 | New Buy | 187,618 | $3.47 |
| Q2 2025 | -17,496 | Sold Out | 0 | $0.00 |
| Q1 2025 | -371,863 | Reduce 95.51% | 17,496 | $4.01 |
| Q4 2024 | +389,359 | New Buy | 389,359 | $6.49 |
| Q1 2023 | -812,662 | Sold Out | 0 | $0.00 |
| Q4 2022 | +139,175 | Add 20.66% | 812,662 | $10.21 |
| Q3 2022 | -862,592 | Reduce 56.16% | 673,487 | $14.72 |
| Q2 2022 | +905,079 | Add 143.44% | 1.54 M | $10.73 |
| Q1 2022 | +631,000 | New Buy | 631,000 | $10.78 |
Steven Cohen's Cytek Biosciences Investment FAQs
Steven Cohen first purchased Cytek Biosciences, Inc. (CTKB) in Q1 2022, acquiring 631,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Cytek Biosciences, Inc. (CTKB) for 12 quarters since Q1 2022.
Steven Cohen's largest addition to Cytek Biosciences, Inc. (CTKB) was in Q2 2022, adding 1,536,079 shares worth $16.48 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 422,361 shares of Cytek Biosciences, Inc. (CTKB), valued at approximately $1.87 M.
As of the Q2 2026 filing, Cytek Biosciences, Inc. (CTKB) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Cytek Biosciences, Inc. (CTKB) was 1,536,079 shares, as reported at the end of Q2 2022.